Global Healthcare Analyst

Tina Banerjee

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/nanosonics-ltd" target="_blank" data-smartkarma-citation="entities:3831:1" rel="noopener">Nanosonics Ltd (NAN AU)</a> reported significant turnaround, with recording H2FY24 revenue of A$90M, up 14% over the first half, driven by 20% increase in capital revenue in H2 over H1.</li>
<li>For FY25, Nanosonics guided for accelerated revenue growth of 8–12%, driven by growing capital revenue with greater unit volumes and increasing recurring revenue aligned with growth in installed base.</li>
<li>The company expects FY25 gross profit margin of 77–79% versus 77.9% in FY24, on higher production volumes in FY25 after reducing inventory in FY24.</li>
</ul>



Nanosonics Ltd (NAN AU) reported significant turnaround, with recording H2FY24 revenue of A$90M, up 14% over the first half, driven by 20% increase in capital revenue in H2 over H1.
For FY25, Nanosonics guided for accelerated revenue growth of 8–12%, driven by growing capital revenue with greater unit volumes and increasing recurring revenue aligned with growth in installed base.
The company expects FY25 gross profit margin of 77–79% versus 77.9% in FY24, on higher production volumes in FY25 after reducing inventory in FY24.


Nanosonics Ltd (NAN AU): Steering Back to Growth Trajectory; Outlook Is Improving

Head of Research, IPOs & Placements, Aequitas Research

Sumeet Singh

Head of Research, IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Blue Jet Healthcare / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/blue-jet-healthcare-ltd" target="_blank" data-smartkarma-citation="entities:36373:1" rel="noopener">Blue Jet Healthcare Ltd (BJHC IN)</a>  is looking to raise about US$300m in its upcoming India IPO.</li>
<li>Blue Jet Healthcare (BJH) is a specialty pharmaceutical and healthcare ingredient and intermediate company, offering niche products targeted toward innovator pharmaceutical companies and multinational generic pharmaceutical companies. </li>
<li>In this note, we look at the company's past performance.</li>
</ul>



Blue Jet Healthcare Ltd (BJHC IN)  is looking to raise about US$300m in its upcoming India IPO.
Blue Jet Healthcare (BJH) is a specialty pharmaceutical and healthcare ingredient and intermediate company, offering niche products targeted toward innovator pharmaceutical companies and multinational generic pharmaceutical companies. 
In this note, we look at the company's past performance.


Blue Jet Healthcare Pre-IPO - Marquee Clients but Inconsistent Growth and Margins

United States

GE HealthCare Technologies Inc. provides medical technology, pharmaceutical diagnostics, and digital solutions. The Company offers imaging, ultrasound, maternal, ventilator, and patient monitoring equipment, as well as performance management, cybersecurity, technical training, site planning, integrated asset optimization, and clinical network solutions.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

GE HealthCare Technologies (GEHC US)

Nanosonics Ltd (NAN AU): Steering Back to Growth Trajectory; Outlook Is Improving

Nanosonics recorded 14% revenue growth in H2FY24 over H1FY24, driven by product revenue. The company anticipates accelerated revenue growth of...

Tina Banerjee

Blue Jet Healthcare Pre-IPO - Marquee Clients but Inconsistent Growth and Margins

Blue Jet Healthcare Ltd (BJHC IN) is looking to raise about US$300m in its upcoming India IPO. In this note, we talk about the past performance.

Sumeet Singh

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Nanosonics Ltd (NAN AU): Steering Back to Growth Trajectory; Outlook Is Improving

​Nanosonics recorded 14% revenue growth in H2FY24 over H1FY24, driven by product revenue. The company anticipates accelerated revenue growth of...

Tina Banerjee

Blue Jet Healthcare Pre-IPO - Marquee Clients but Inconsistent Growth and Margins

Blue Jet Healthcare Ltd (BJHC IN) is looking to raise about US$300m in its upcoming India IPO. In this note, we talk about the past performance.

Sumeet Singh

Nanosonics recorded 14% revenue growth in H2FY24 over H1FY24, driven by product revenue. The company anticipates accelerated revenue growth of...